Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

76.19USD
24 Nov 2017
Change (% chg)

$0.55 (+0.73%)
Prev Close
$75.64
Open
$75.37
Day's High
$76.85
Day's Low
$74.76
Volume
37,809
Avg. Vol
141,542
52-wk High
$95.78
52-wk Low
$25.30

Select another date:

Tue, Nov 14 2017

Photo

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

UPDATE 4-Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Nov 14 Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

UPDATE 2-Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal

Nov 14 Loxo Oncology will collaborate with Germany's Bayer to develop and commercialize two of its cancer therapies, the companies said, in a deal that could bring the U.S. drug developer up to $1.55 billion over the next few years.

BRIEF-Bayer, Loxo Oncology form partnership to develop, commercialise cancer drugs​

* Says it and loxo oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer​

BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs

* Loxo Oncology announces global development and commercialization partnership with Bayer for larotrectinib and LOXO-195

Loxo Oncology to develop, commercialize cancer drugs with Bayer

Nov 14 U.S. drug developer Loxo Oncology Inc on Tuesday announced a deal with Bayer AG to develop and commercialize two of its cancer therapies and said it would receive $400 million upfront.

BRIEF-Loxo Oncology reports quarterly loss per share of ‍$2.45

* Loxo Oncology announces third quarter 2017 financial results

BRIEF-Loxo Oncology announces positive results from independent review committee assessment of larotrectinib dataset

* Loxo Oncology announces positive top-line results from independent review committee assessment of larotrectinib dataset

BRIEF-Loxo Oncology posts Q3 loss per share $1.14

* Loxo Oncology announces second quarter 2017 financial results

BRIEF-Loxo Oncology acquires BTK inhibitor program

* Loxo Oncology announces acquisition of highly selective, reversible BTK inhibitor program

Select another date: